The stock's rise snapped a four-day losing streak.

Fintel reports that on February 28, 2025, Stifel downgraded their outlook for Vertex (NasdaqGM:VERX) from Buy to Hold.

Vertex, Inc. (NASDAQ:VERX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the company, MarketBeat.com reports.

Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

Baird lowered the firm’s price target on Vertex (VERX) to $45 from $62 and keeps an Outperform rating on the shares. The firm updated its model ...

BMO Capital analyst Daniel Jester lowered the firm’s price target on Vertex (VERX) to $41 from $56 and keeps a Market Perform rating on the ...

We recently compiled a list of the 10 Stocks Drop by Double Digits Mostly Due to Disappointing Earnings. In this article, we ...

Arc'teryx’s new footwear models will be available globally, launching throughout 2025. The Norvan LD 4 arrives in March, ...

Private foundations providing support, resources, and advocacy for individuals and families affected by rare diseases have ...

When MTV launched in 1981, the first video it aired was The Buggles' "Video Killed the Radio Star." This music trivia comes ...

In Vermont, no day goes by without another news story about the lack of affordable, workforce, and senior housing.

About the company: SurgeGraph Vertex is an AI writing tool with a mission to help users grow their website traffic through ...